Primary Tumor Levels of Human Tissue Kallikreins Affect Surgical Success and Survival in Ovarian Cancer Patients
- 15 March 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (6) , 1742-1748
Abstract
Purpose: Proteolytic factors of the human tissue kallikrein (hK) family and the plasminogen activation system play a key role in tumor progression in various malignancies. We determined antigen levels of urokinase-type plasminogen activator (uPA), its inhibitor PAI-1, and hK5-8, hK10, hK11, and hK13 by ELISA in primary tumor tissue extracts of 142 International Federation of Gynecology and Obstetrics (FIGO) I to IV ovarian cancer patients (median follow-up 41 months). Results: After radical surgery, absence of macroscopically visible residual tumor (RT) was achieved in 72 patients; all patients received postoperative platinum-containing chemotherapy. Significant univariate predictors of poor progression-free survival (PFS) were RT (>0), FIGO stages (III/IV versus I/II/III), ascites volume >500 mL, nodal status, and the difference between PAI-1 and uPA (fractionally ranked). In multivariate analysis, significant independent factors for poor PFS were RT [hazard ratio (HR), 4.53] and low hK11 fractional rank (HR, 0.30). Univariate predictors of poor overall survival were RT, FIGO stages, nodal status, ascites volume, nuclear grade, and low hK10 and hK13. In multivariate analysis, significant independent factors for poor overall survival were RT (HR, 7.49), ascites (HR, 1.97), and low hK10 (HR, 0.196). We constructed a multivariate scoring model estimating RT probability, based on ascites [odds ratio (OR), 13.1], nuclear grade (OR, 2.92), hK6 (OR, 8.54), and hK13 (OR, 0.14), with good in-sample predictive performance (area under receiver operating characteristic, 0.833). Conclusions: In view of risks and benefits of radical surgery, such a score could support preoperative risk stratification and identify candidates for alternative therapeutic strategies. These results highlight the distinct roles of the hKs for different disease end points in ovarian cancer and their potential to support individualized therapy decisions.Keywords
This publication has 24 references indexed in Scilit:
- Potential markers that complement expression of CA125 in epithelial ovarian cancerGynecologic Oncology, 2005
- Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical TrialJNCI: Journal of the National Cancer Institute, 2005
- Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patientsClinical Biochemistry, 2004
- Human Kallikrein Gene 11 ( KLK11 ) mRNA Overexpression Is Associated with Poor Prognosis in Patients with Epithelial Ovarian CancerClinical Cancer Research, 2004
- Development of an Immunofluorometric Assay and Quantification of Human Kallikrein 7 in Tissue Extracts and Biological FluidsClinical Chemistry, 2004
- Human Kallikrein 13 Protein in Ovarian Cancer Cytosols: A New Favorable Prognostic MarkerJournal of Clinical Oncology, 2004
- Carcinoma of the ovaryInternational Journal of Gynecology & Obstetrics, 2003
- Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinomaInternational Journal of Cancer, 2003
- Urokinase (uPA) and PAI-1 Predict Survival in Advanced Ovarian Cancer Patients (FIGO III) after Radical Surgery and Platinum-Based ChemotherapyGynecologic Oncology, 1994
- Enzymically amplified time-resolved fluorescence immunoassay with terbium chelatesAnalytical Chemistry, 1992